Alvotech Strikes $45m Deal With Yas
Biosimilars Deal Includes 2.5% Stake And MENA Rights
Alvotech has struck an investment deal worth $45m with Yas Holding that will give Yas a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.
You may also be interested in...
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Alvogen has struck a licensing deal with Yas Holding that gives the firm exclusive distribution rights to a portfolio of 28 generics in the Middle East and North Africa region from 2020.